Mifepristone – USA

Mifepristone – USA

IPR decision: Feb 10, 2020

AIA Review #
Filing Date
Institution Date
Petitioner
Patent
Respondent
FINAL WRITTEN DECISION
IPR2018-01494
08/02/2018
02/15/2019
Neptune Generics LLC
8,921,348
Corcept Therapeutics Inc.
Claims 1-7 are patentable
US 8,921,348 (Corcept Therapeutics, Inc.; Exp: 08/27/2028) – listed in OB

1. A method for optimizing levels of mifepristone in a patient suffering from a disorder amenable to treatment by mifepristone, the method comprising: treating the patient with seven or more daily doses of mifepristone over a period of seven or more days; testing the serum levels of the patient to determine whether the blood levels of mifepristone are greater than 1300 ng/mL; and adjusting the daily dose of the patient to achieve mifepristone blood levels greater than 1300 ng/mL.

Leave a Reply

Leave a Reply

Your email address will not be published.

Disclaimer
All content provided on this blog is for informational purposes only. By using the blog, you agree that the information on this blog does not constitute legal or other professional advice on author's or on his company's behalf.

Copyrights 2022 Pharma IP Circle. All Rights Reserved